Yearly Archives: 2020

Gilead will buy cancer drug maker Immunomidics for 21 billion

(Reuters) – Gilead Sciences Inc. The biopharmaceutical company will receive Immunomidics Inc. The two companies said in a joint statement on Sunday that for 21 21 billion, a move that would strengthen its cancer portfolio by acquiring promising drugs by access. The deal provides access to Immunomidix’s breast cancer treatment, …

Read More »